These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12700345)

  • 1. Human apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins.
    Kotite L; Zhang LH; Yu Z; Burlingame AL; Havel RJ
    J Lipid Res; 2003 Jul; 44(7):1387-94. PubMed ID: 12700345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification, characterization, cloning, and expression of apolipoprotein C-IV, a novel sialoglycoprotein of rabbit plasma lipoproteins.
    Zhang LH; Kotite L; Havel RJ
    J Biol Chem; 1996 Jan; 271(3):1776-83. PubMed ID: 8576182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and metabolic characteristics of an apolipoprotein C-II variant isolated from a hypertriglyceridemic subject.
    Huff MW; Evans AJ; Wolfe BM; Connelly PW; Maguire GF; Strong WL
    J Lipid Res; 1990 Mar; 31(3):385-96. PubMed ID: 2341805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
    Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
    J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice.
    Allan CM; Taylor JM
    J Lipid Res; 1996 Jul; 37(7):1510-8. PubMed ID: 8827523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
    Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS
    J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein.
    Weisgraber KH; Mahley RW; Kowal RC; Herz J; Goldstein JL; Brown MS
    J Biol Chem; 1990 Dec; 265(36):22453-9. PubMed ID: 2266137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lipid transport system in the mouse, Mus musculus: isolation and characterization of apolipoproteins B, A-I, A-II, and C-III.
    Forgez P; Chapman MJ; Rall SC; Camus MC
    J Lipid Res; 1984 Sep; 25(9):954-66. PubMed ID: 6436419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
    Campos H; Perlov D; Khoo C; Sacks FM
    J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
    Breyer ED; Le NA; Li X; Martinson D; Brown WV
    J Lipid Res; 1999 Oct; 40(10):1875-82. PubMed ID: 10508207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects.
    Cohn JS; Tremblay M; Batal R; Jacques H; Veilleux L; Rodriguez C; Bernier L; Mamer O; Davignon J
    J Lipid Res; 2002 Oct; 43(10):1680-7. PubMed ID: 12364552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins.
    Bukberg PR; Le NA; Ginsberg HN; Gibson JC; Rubinstein A; Brown WV
    J Lipid Res; 1985 Sep; 26(9):1047-57. PubMed ID: 4067427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein.
    Bondarenko PV; Cockrill SL; Watkins LK; Cruzado ID; Macfarlane RD
    J Lipid Res; 1999 Mar; 40(3):543-55. PubMed ID: 10064743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
    Mann CJ; Troussard AA; Yen FT; Hannouche N; Najib J; Fruchart JC; Lotteau V; André P; Bihain BE
    J Biol Chem; 1997 Dec; 272(50):31348-54. PubMed ID: 9395464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of recombinant human apolipoprotein C-II expressed in Escherichia coli.
    Wang CS; Downs D; Dashti A; Jackson KW
    Biochim Biophys Acta; 1996 Aug; 1302(3):224-30. PubMed ID: 8765143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.
    Goldberg IJ; Scheraldi CA; Yacoub LK; Saxena U; Bisgaier CL
    J Biol Chem; 1990 Mar; 265(8):4266-72. PubMed ID: 2307668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of cholesteryl ester transfer protein inhibitor from plasma of baboons (Papio sp.).
    Kushwaha RS; Hasan SQ; McGill HC; Getz GS; Dunham RG; Kanda P
    J Lipid Res; 1993 Aug; 34(8):1285-97. PubMed ID: 8409763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis.
    Björkegren J; Silveira A; Boquist S; Tang R; Karpe F; Bond MG; de Faire U; Hamsten A
    Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1470-4. PubMed ID: 12231568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients.
    Marcoux C; Tremblay M; Nakajima K; Davignon J; Cohn JS
    J Lipid Res; 1999 Apr; 40(4):636-47. PubMed ID: 10191287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.